Clinical trials: Non-Small Cell Lung Cancer Stage IIIB
Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Docetaxel and Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00390429
- Testing
- docetaxel, erlotinib hydrochloride
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- University of California, Davis
Non Small Cell Lung Cancer
Eribulin Mesylate Administered in Combination With Pemetrexed Versus Pemetrexed Alone as Second Line Therapy in Patients With Stage IIIB or IV Nonsquamous Non Small Cell Lung Cancer
The purpose of this study is to determine whether Eribulin Mesylate Administered in Combination with Pemetrexed is safe and tolerable and to gain a preliminary indication of clinical benefit when administered to Patients with…
- Trial name
- NCT01126736
- Testing
- eribulin mesylate, pemetrexed, Eribulin mesylate (eribulin; E7389)
- Where
- 18 sites in United States, Czechia and 3 more
- Volunteers
- 98 people
- Sponsor
- Eisai Inc.
Neoplasms, Metastatic Cancer
Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042
Part A: To test the safety and tolerability of combination therapy with Niraparib and TSR-042 and to establish a safe dose that will be used in a Phase 2 study.
- Conditions
- Neoplasms, Metastatic Cancer, Advanced Cancer, Solid Tumor
- Trial name
- NCT03307785
- Testing
- Niraparib, TSR-042, Carboplatin-Paclitaxel
- Where
- 8 sites in United States
- Volunteers
- 60 people
- Sponsor
- Tesaro, Inc.
Lung Cancer
Pemetrexed Disodium, Carboplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Stage III Non-Small Cell Lung Cancer
RATIONALE: Pemetrexed disodium may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as carboplatin, work in different ways to stop the growth of tumor cells…
- Trial name
- NCT00117962
- Testing
- cetuximab, carboplatin, pemetrexed disodium
- Where
- 71 sites in United States
- Volunteers
- 109 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Carboplatin and Paclitaxel Combined With Cetuximab and/or IMC-A12 in Patients With Advanced Non-Small Cell Lung Cancer
This randomized phase II trial is studying how well giving carboplatin and paclitaxel together with cetuximab and/or cixutumumab (IMC-A12) works in treating patients with stage IIIB or stage IV non-small cell lung cancer.
- Conditions
- Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Trial name
- NCT00986674
- Testing
- cixutumumab, carboplatin, paclitaxel
- Where
- 249 sites in United States
- Volunteers
- 140 people
- Sponsor
- National Cancer Institute (NCI)
Lung Cancer
Radiation Therapy in Preventing Central Nervous System (CNS) Metastases in Patients With Non-Small Cell Lung Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known if giving radiation therapy to the head is effective in preventing CNS metastases in patients who have stage III non-small cell lung…
- Trial name
- NCT00048997
- Testing
- Radiation therapy, Observation
- Where
- 14 sites in United States
- Volunteers
- 356 people
- Sponsor
- Radiation Therapy Oncology Group
Non-Small Cell Lung Cancer
A Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Resectable Non-Small Cell Lung Cancer (NSCLC) - Lung Cancer Mutation Consortium (LCMC3)
This study was designed to evaluate the safety and efficacy of neoadjuvant and adjuvant atezolizumab in participants with resectable Non-Small Cell Lung Cancer (NSCLC).
- Trial name
- NCT02927301
- Testing
- Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody
- Where
- 19 sites in United States
- Volunteers
- 181 people
- Sponsor
- Genentech, Inc.
Recurrent Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer
Azacitidine and Entinostat in Treating Patients With Recurrent Advanced Non-Small Cell Lung Cancer
This phase I/II trial is studying the side effects and best dose of azacitidine when given together with entinostat and to see how well they work in treating patients with recurrent advanced non-small cell lung cancer.
- Conditions
- Recurrent Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
- Trial name
- NCT00387465
- Testing
- Azacitidine 30mg/m2, Entinostat, Azacitidine 40mg/m2
- Where
- 5 sites in United States
- Volunteers
- 94 people
- Sponsor
- National Cancer Institute (NCI)
Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV
Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment.
The purpose of this study is to treat patients with locally advanced or metastatic NSCLC with a combination therapy of selumetinib and two different doses of docetaxel 75mg/m2 or 60 mg/m2 vs placebo and compare how well each dose…
- Trial name
- SELECT-2 (NCT01750281)
- Testing
- Selumetinib 75 mg, Docetaxel 75 mg/m2, Docetaxel 60 mg/m2
- Where
- 68 sites in United States, Brazil and 6 more
- Volunteers
- 212 people
- Sponsor
- AstraZeneca
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies
This phase I trial studies the side effects and best dose of genetically modified T-cell therapy in treating patients with receptor tyrosine kinase-like orphan receptor 1 positive (ROR1+) chronic lymphocytic leukemia (CLL)…
- Conditions
- Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Triple-Negative Breast Carcinoma
- Trial name
- NCT02706392
- Testing
- Laboratory Biomarker Analysis, ROR1 CAR-specific Autologous T-Lymphocytes
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Fred Hutchinson Cancer Center
Non Small Cell Lung Cancer
Zalutumumab in Combination With Chemo-Radiation in a Certain Type of Lung Cancer
The purpose of the study is to investigate if treatment with zalutumumab in combination with chemotherapy and radiotherapy (chemo-radiation) will lead to a prolonged life in patients with lung cancer compared to patients treated…
- Trial name
- NCT00460551
- Testing
- Zalutumumab, Induction chemotherapy, Radiotherapy
- Where
- 8 sites in United States, Belgium and 3 more
- Volunteers
- 13 people
- Sponsor
- Genmab
Lung Cancer
Photodynamic Therapy Using HPPH in Treating Patients With Advanced Non-Small Cell Lung Cancer That Blocks the Air Passages
RATIONALE: Photodynamic therapy uses a drug, such as HPPH, that becomes active when it is exposed to a certain kind of light. When the drug is active, tumor cells are killed.
- Trial name
- NCT00528775
- Testing
- HPPH, endoscopic procedure
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Roswell Park Cancer Institute
Lung Cancer
Cisplatin, Pemetrexed Disodium, and Radiation Therapy Followed by Docetaxel in Treating Patients With Stage III Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as cisplatin, pemetrexed disodium, and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00301808
- Testing
- Cisplatin, Docetaxel, Pemetrexed disodium
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Non-small Cell Lung Cancer
Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)
This study is an open label, multicenter, randomized phase II trial of consolidation immunotherapy with either nivolumab alone or the combination of nivolumab and ipilimumab following concurrent chemoradiation in patients with…
- Trial name
- NCT03285321
- Testing
- Nivolumab, Ipilimumab
- Where
- 12 sites in United States
- Volunteers
- 105 people
- Sponsor
- Greg Durm, MD
Recurrent Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer
Pemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating Patients With Advanced Non-small Cell Lung Cancer
This randomized phase III trial studies pemetrexed disodium to see how well it works compared with erlotinib hydrochloride as second-line therapy in treating patients with non-small cell lung cancer that has spread to other…
- Conditions
- Recurrent Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
- Trial name
- MARVEL (NCT00738881)
- Testing
- Erlotinib Hydrochloride, Pemetrexed Disodium
- Where
- 269 sites in United States, Canada
- Volunteers
- 23 people
- Sponsor
- National Cancer Institute (NCI)
Unresectable Stage III NSCLC
Mobile Devices to Detect Early Pneumonitis in Stage III NSCLC Patients on Durvalumab.
A study of whether mobile devices can improve the detection of pulmonary AEs (including pneumonitis) in stage III NSCLC patients post-CRT, while on durvalumab.
- Trial name
- ON TRAX (NCT04381494)
- Testing
- Multiparametric Mobile Technology
- Where
- 18 sites in United States
- Volunteers
- 40 people
- Sponsor
- AstraZeneca
Recurrent Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer
Azacitidine and Entinostat Before Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer
This randomized phase II trial studies how well azacitidine and entinostat before chemotherapy works in treating patients with non-small cell lung cancer that has spread to other places in the body.
- Conditions
- Recurrent Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
- Trial name
- NCT01935947
- Testing
- Azacitidine, Docetaxel, Entinostat
- Where
- 5 sites in United States
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
Non-small Cell Lung Cancer Metastatic, Non-small Cell Lung Cancer Stage IIIB
Survival Prolongation by Rationale Innovative Genomics
Patients with advanced/metastatic non-small cell lung cancer (NSCLC) with no documented targetable alterations (Epidermal Growth Factor Receptor (EGFR) mutation, Anaplastic Lymphoma Kinase (ALK) translocation, ROS1 mutation if…
- Trial name
- SPRING (NCT03386929)
- Testing
- Avelumab, Axitinib, Palbociclib
- Where
- 5 sites in United States, Israel and 2 more
- Volunteers
- 15 people
- Sponsor
- Worldwide Innovative Network Association
Stage IIB Non-Small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer
Magnetic Resonance-Guided Hypofractionated Adaptive Radiation Therapy With Concurrent Chemotherapy and Consolidation Durvalumab for Inoperable Stage IIB, IIIA, and Select IIIB and IIIC Non-small Cell Lung Cancer
Building upon the clinical experience of the investigators with the magnetic resonance (MR)-guided radiation therapy system and applying principals of hypofractionation toward the current treatment paradigm of concurrent…
- Conditions
- Stage IIB Non-Small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IIIC Non-Small Cell Lung Cancer
- Trial name
- NCT03916419
- Testing
- ViewRay MR-Linear Accelerator, Radiation therapy, Paclitaxel
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Washington University School of Medicine
Lung Cancer
Pemetrexed Disodium and Cisplatin in Treating Patients Who Are Undergoing Surgery for Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as pemetrexed disodium and cisplatin work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00248495
- Testing
- cisplatin, pemetrexed disodium, adjuvant therapy
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Roswell Park Cancer Institute